Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study | Zendy

Karen R. Jacobson | Zendy; Marinus Barnard | Zendy; Mary B. Kleinman | Zendy; Elizabeth M. Streicher | Zendy; Elizabeth J. Ragan | Zendy; Laura F. White | Zendy; Ofer Shapira | Zendy; Tania Dolby | Zendy; John Simpson | Zendy; Lesley Scott | Zendy; Wendy Stevens | Zendy; Paul D. van Helden | Zendy; Annelies Van Rie | Zendy; Robin M. Warren | Zendy

Open Access

Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study

Author(s) -

Karen R. Jacobson,

Marinus Barnard,

Mary B. Kleinman,

Elizabeth M. Streicher,

Elizabeth J. Ragan,

Laura F. White,

Ofer Shapira,

Tania Dolby,

John Simpson,

Lesley Scott,

Wendy Stevens,

Paul D. van Helden,

Annelies Van Rie,

Robin M. Warren

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix128

Subject(s) - medicine , tuberculosis , rifampicin , ethionamide , regimen , pyrazinamide , isoniazid , drug resistance , mycobacterium tuberculosis , surgery , ethambutol , pathology , microbiology and biotechnology , biology

Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a World Health Organization-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results. We quantified the second-line DST results time and proportion of patients potentially placed on suboptimal therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research